VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter